Yourgene Health PLC Directorate Change (0972A)

TIDMYGEN

RNS Number : 0972A

Yourgene Health PLC

22 May 2023

Yourgene Health plc

("Yourgene", the "Group" or the "Company")

Directorate Change

Manchester , UK - 22 May 2023: Yourgene (AIM: YGEN), a leading international molecular diagnostic group, announces the reappointment of Dr. Joanne Mason, Chief Scientific Officer, as a Director of the Company with immediate effect.

Dr. Mason has been leading the development of Yourgene's next generation molecular diagnostics, in particular in the area of reproductive health, helping the Company deliver on its new product roadmap and commercial success. Given Dr Mason's background and experience in this field, she is playing an increasingly pivotal role for the Company in highlighting the technical benefits of the Company's offerings to potential and existing customers, and her expertise provides an important complement to the skills and understanding of the wider Board.

Disclosures in accordance with the AIM Rules

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of Dr. Joanne Nicola Mason (aged 49):

 
 Current appointments   Former appointments in the 
                         past 5 years 
 Yourgene Health        Yourgene Health plc 
  UK Ltd

Dr. Mason holds 7,509,480 ordinary shares and 1,000,000 options over new ordinary shares in the Company.

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                           Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                                        investors@yourgenehealth.com 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                          Tel: +44 (0)20 7213 0880 
Liam Murray / Ludovico Lazzaretti 
 
Singer Capital Markets (Corporate Broker)                                     Tel: +44 (0)20 7496 3000 
Aubrey Powell / Tom Salvesen / George Tzimas 
 
Walbrook PR Ltd (Media and Investor Relations)     Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
Paul McManus / Alice Woodings / Lianne Applegarth                   Mob: 07980 541 893 / 07407 804 654 
                                                                                       / 07584 391 303

About Yourgene Health

Yourgene Health is an international integrated technologies and services business, enabling the delivery of genomic medicine. The Group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic and screening solutions, for reproductive health and precision medicine. The Group's portfolio of in vitro diagnostic products includes non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping assays.

Building on our expertise in genomic technology, Yourgene's Ranger(R) Technology offers next generation size selection with a range of sample preparation platforms for dynamic target enrichment. Ranger(R) Technology can be utilised to improve workflows and performance in multiple applications including NIPT, oncology, infectious disease testing and gene synthesis.

Yourgene Genomic Services offers a clinical service from UK and Taiwan focusing on precision medicine and reproductive health, including NIPT.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN".

For more information visit https://yourgenehealth.com/ and follow us on twitter @Yourgene_Health.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAGPUCWAUPWGQB

(END) Dow Jones Newswires

May 22, 2023 02:00 ET (06:00 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024